Lab Med Online.  2021 Oct;11(4):290-296. 10.47429/lmo.2021.11.4.290.

Evaluation of the AccuPower^® RV1 Real-Time RT-PCR Kit and the AccuPower^® RV1 Multiplex Kit for SARS-CoV-2 and Influenza Virus Detection

• Kim MJ
• Park H
• Jeon YL
• Shin HS
• Cho SI
• Kim B
• Lee JS
• Park SS
• Seong MW

• KMID: 2526091
• DOI: http://doi.org/10.47429/lmo.2021.11.4.290

Abstract

Background
The AccuPower^® RV1 Real-Time RT-PCR Kit (Bioneer, Korea) and AccuPower^® RV1 Multiplex Kit (Bioneer) are one-step real-time reverse transcription PCR assays for detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza A and B.
Methods
We clinically evaluated the AccuPower^® RV1 Real-Time RT-PCR Kit and AccuPower^® RV1 Multiplex Kit by comparing their results for 1,098 clinical samples. The presence of SARS-CoV-2 was confirmed using the Allplex™ 2019-nCoV Assay (Seegene, Korea) and Standard M nCoV Real-Time Detection Kit (SD Biosensor, Korea). Influenza viruses were detected using the Allplex™ Respiratory Panel 1 (Seegene).
Results
The comparative positive and negative agreement values of the AccuPower^® RV1 Real-Time RT-PCR Kit for SARS-CoV-2 and influenza A and B were 100%. The positive agreement of the AccuPower^® RV1 Multiplex Kit was 100% for SARS-CoV-2 and 98.77% for influenza A and B. The kappa values for SARS-CoV-2 and influenza A and B were > 0.99. SARS-CoV-2 was evaluated using both sputum and nasopharyngeal or oropharyngeal swabs. There was no difference in the detection rates for each type.
Conclusions
The findings confirm the clinically comparable performances of the AccuPower^® RV1 Real-Time RT-PCR Kit and the AccuPower^® RV1 Multiplex Kit.

Keyword

SARS-CoV-2; Influenza virus; Multiplex real-time PCR; Clinical evaluation

Reference

1. Kong WH, Li Y, Peng MW, Kong DG, Yang XB, Wang L, et al. 2020; SARS-CoV-2 detection in patients with influenza-like illness. Nat Microbiol. 5:675–8. DOI: 10.1038/s41564-020-0713-1. PMID: 32265517.

2. Guo JJ, Yu YH, Ma XY, Liu YN, Fang Q, Qu P, et al. 2020; A multiple-center clinical evaluation of a new real-time reverse transcriptase PCR diagnostic kit for SARS-CoV-2. Future Virol. 10.2217/fvl-2020-0299. DOI: 10.2217/fvl-2020-0299. PMID: 33576582. PMCID: PMC7594197.

3. Attwood LO, Francis MJ, Hamblin J, Korman TM, Druce J, Graham M. 2020; Clinical evaluation of AusDiagnostics SARS-CoV-2 multiplex tandem PCR assay. J Clin Virol. 128:104448. DOI: 10.1016/j.jcv.2020.104448. PMID: 32460173. PMCID: PMC7236671.

4. Singer BD. 2020; COVID-19 and the next influenza season. Sci Adv. 6:eabd0086. DOI: 10.1126/sciadv.abd0086. PMID: 32789184. PMCID: PMC7399656.

5. Bai L, Zhao Y, Dong J, Liang S, Guo M, Liu X, et al. 2021; Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res. 31:395–403. DOI: 10.1038/s41422-021-00473-1. PMID: 33603116. PMCID: PMC7890106.

6. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. 2020; Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emerg Infect Dis. 26:1324–6. DOI: 10.3201/eid2606.200299. PMID: 32160148. PMCID: PMC7258479.

7. Cuadrado-Payán E, Montagud-Marrahi E, Torres-Elorza M, Bodro M, Blasco M, Poch E, et al. 2020; SARS-CoV-2 and influenza virus co-infection. Lancet. 395:e84. DOI: 10.1016/S0140-6736(20)31052-7. PMID: 32423586. PMCID: PMC7200126.

8. Chung HY, Jian MJ, Chang CK, Lin JC, Yeh KM, Chen CW, et al. 2021; Novel dual multiplex real-time RT-PCR assays for the rapid detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus using the BD MAX open system. Emerg Microbes Infect. 10:161–6. DOI: 10.1080/22221751.2021.1873073. PMID: 33410371. PMCID: PMC7832498.

9. Mancini F, Barbanti F, Scaturro M, Fontana S, Di Martino A, Marsili G, et al. 2021; Multiplex real-time reverse-transcription polymerase chain reaction assays for diagnostic testing of severe acute respiratory syndrome coronavirus 2 and seasonal influenza viruses: A challenge of the phase 3 pandemic setting. J Infect Dis. 223:765–74. DOI: 10.1093/infdis/jiaa658. PMID: 33080031. PMCID: PMC7665649.

10. Clinical and Laboratory Standards Institute. 2012. Evaluation of detection capability for clinical laboratory measurement procedures; Approved guideline-Second edition, CLSI document EP17-A2. Clinical and Laboratory Standards Institute;Wayne, PA:

11. Alosaimi B, Naeem A, Hamed ME, Alkadi HS, Alanazi T, Al Rehily SS, et al. 2021; Influenza co-infection associated with severity and mortality in COVID-19 patients. Virol J. 18:127. DOI: 10.1186/s12985-021-01594-0. PMID: 34127006. PMCID: PMC8200793.

12. D'Abramo A, Lepore L, Palazzolo C, Barreca F, Liuzzi G, Lalle E, et al. 2020; Acute respiratory distress syndrome due to SARS-CoV-2 and Infuenza A co-infection in an Italian patient: Mini-review of the literature. Int J Infect Dis. 97:236–9. DOI: 10.1016/j.ijid.2020.06.056. PMID: 32565366. PMCID: PMC7301795.

13. Konala VM, Adapa S, Gayam V, Naramala S, Daggubati SR, Kammari CB, et al. 2020; Co-infection with Infuenza A and COVID-19. Eur J Case Rep Intern Med. 7:001656. DOI: 10.12890/2020_001656. PMID: 32399452. PMCID: PMC7213830.

14. Mohammadi A, Esmaeilzadeh E, Li Y, Bosch RJ, Li JZ. 2020; SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis. EBioMedicine. 59:102903. DOI: 10.1016/j.ebiom.2020.102903. PMID: 32718896. PMCID: PMC7380223.

15. Yu F, Qiu T, Zeng Y, Wang Y, Zheng S, Chen X, et al. 2018; Comparative evaluation of three preprocessing methods for extraction and detection of influenza A virus nucleic acids from sputum. Front Med. 5:56. DOI: 10.3389/fmed.2018.00056. PMID: 29552562. PMCID: PMC5840144.

16. Lin C, Xiang J, Yan M, Li H, Huang S, Shen C. 2020; Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19). Clin Chem Lab Med. 58:1089–94. DOI: 10.1515/cclm-2020-0187. PMID: 32301745.